Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALBNYSE:ARCNASDAQ:CRDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBAlbemarle$57.73-0.8%$68.61$49.43▼$137.50$6.79B1.592.74 million shs3.07 million shsARCARC Document Solutions$3.39$3.39$2.56▼$3.44$146.65M1.13222,468 shsN/ACRDLCardiol Therapeutics$1.08+0.9%$1.05$0.77▼$3.12$88.39M1383,570 shs81,045 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBAlbemarle0.00%+9.18%-22.77%-34.92%-49.92%ARCARC Document Solutions0.00%0.00%0.00%0.00%+23.72%CRDLCardiol Therapeutics0.00%+6.93%+9.09%-26.03%-38.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBAlbemarle4.0156 of 5 stars4.11.02.50.62.31.71.3ARCARC Document SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACRDLCardiol Therapeutics1.8989 of 5 stars3.62.00.00.02.40.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBAlbemarle 2.15Hold$96.0566.38% UpsideARCARC Document Solutions 4.00Strong BuyN/AN/ACRDLCardiol Therapeutics 3.29Buy$8.40677.78% UpsideCurrent Analyst Ratings BreakdownLatest SYME, CRDL, ARC, and ALB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/15/2025ALBAlbemarleCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$85.00 ➝ $64.004/15/2025ALBAlbemarleRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$77.00 ➝ $60.004/14/2025ALBAlbemarleKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$122.00 ➝ $102.004/14/2025ALBAlbemarleTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$85.00 ➝ $65.004/9/2025ALBAlbemarleWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$80.00 ➝ $60.004/7/2025ALBAlbemarleUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$86.00 ➝ $64.004/7/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/7/2025ALBAlbemarleMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$90.00 ➝ $85.002/24/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.002/20/2025ALBAlbemarlePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$90.00 ➝ $85.00(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBAlbemarle$5.38B1.26$2.72 per share21.21$67.76 per share0.85ARCARC Document Solutions$281.20M0.52$0.69 per share4.94$3.62 per share0.94CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBAlbemarle-$1.18B-$11.20N/A30.23N/A-21.93%-1.72%-0.84%4/30/2025 (Estimated)ARCARC Document Solutions$8.23M$0.1130.8216.141.531.61%5.28%2.66%N/ACRDLCardiol Therapeutics-$20.84M-$0.37N/AN/AN/AN/A-194.40%-129.07%5/13/2025 (Estimated)Latest SYME, CRDL, ARC, and ALB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CRDLCardiol Therapeutics-$0.09N/AN/AN/AN/AN/A4/30/2025Q1 2025ALBAlbemarle-$0.37N/AN/AN/A$1.18 billionN/A3/31/2025Q4 2024CRDLCardiol Therapeutics-$0.08-$0.07+$0.01-$0.07N/AN/A2/12/2025Q4 2024ALBAlbemarle-$0.60-$1.09-$0.49$0.29$1.34 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBAlbemarle$1.622.81%+1.06%N/A 30 YearsARCARC Document Solutions$0.205.90%+115.44%181.83%N/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ALatest SYME, CRDL, ARC, and ALB DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/27/2025ALBAlbemarlequarterly$0.40502.05%3/14/20253/14/20254/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBAlbemarle0.391.951.19ARCARC Document Solutions0.331.491.37CRDLCardiol Therapeutics0.012.492.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBAlbemarle92.87%ARCARC Document Solutions48.93%CRDLCardiol Therapeutics12.49%Insider OwnershipCompanyInsider OwnershipALBAlbemarle0.33%ARCARC Document Solutions18.79%CRDLCardiol Therapeutics5.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBAlbemarle7,400117.65 million117.13 millionOptionableARCARC Document Solutions1,90043.26 million35.13 millionOptionableCRDLCardiol Therapeutics2082.61 million78.27 millionNot OptionableSYME, CRDL, ARC, and ALB HeadlinesRecent News About These CompaniesCardiol Therapeutics Stock: Is Cannabis Potential Priced In?April 22, 2025 | zacks.comReviewing Cardiol Therapeutics (NASDAQ:CRDL) and Genocea Biosciences (NASDAQ:GNCA)April 21, 2025 | americanbankingnews.comCardiol Therapeutics (CRDL) Projected to Post Earnings on MondayApril 20, 2025 | marketbeat.comResearch Analysts Offer Predictions for CRDL Q1 EarningsApril 20, 2025 | marketbeat.comCardiol Therapeutics (CRDL) Expected to Announce Earnings on MondayApril 20, 2025 | americanbankingnews.comQ1 EPS Estimate for Cardiol Therapeutics Reduced by AnalystApril 19, 2025 | americanbankingnews.comCardiol Therapeutics starts phase III trial for heart drugApril 18, 2025 | uk.investing.comRoth MKM Sticks to Its Buy Rating for Cardiol Therapeutics (CRDL)April 18, 2025 | markets.businessinsider.comCardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC WainwrightApril 18, 2025 | marketbeat.comCardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent PericarditisApril 16, 2025 | newsfilecorp.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Consensus Rating of "Buy" from BrokeragesApril 15, 2025 | marketbeat.comCardiol Therapeutics Reports Increased Losses Amid Rising ExpensesApril 14, 2025 | tipranks.comWhat is HC Wainwright's Forecast for CRDL FY2025 Earnings?April 12, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL)April 9, 2025 | marketbeat.comWe're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn RateApril 2, 2025 | finance.yahoo.comCardiol Therapeutics (NASDAQ:CRDL) Releases Earnings Results, Beats Expectations By $0.01 EPSApril 1, 2025 | marketbeat.comCardiol Therapeutics Announces Year-End 2024 Update on OperationsApril 1, 2025 | newsfilecorp.comCardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on MondayMarch 31, 2025 | marketbeat.comCardiol Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceMarch 3, 2025 | newsfilecorp.comCardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failureFebruary 20, 2025 | proactiveinvestors.comCardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart FailureFebruary 20, 2025 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Archer Aviation’s Africa Deal Could Boost ACHR StockBy Jeffrey Neal Johnson | April 4, 2025View Archer Aviation’s Africa Deal Could Boost ACHR StockTime to Buy Alibaba and PDD After Tariff Exemptions?By Gabriel Osorio-Mazilli | April 17, 2025View Time to Buy Alibaba and PDD After Tariff Exemptions?Archer Aviation Unveils NYC Network Ahead of Key Earnings ReportBy Jeffrey Neal Johnson | April 18, 2025View Archer Aviation Unveils NYC Network Ahead of Key Earnings ReportBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?By Jea Yu | April 4, 2025View Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?SYME, CRDL, ARC, and ALB Company DescriptionsAlbemarle NYSE:ALB$57.73 -0.44 (-0.76%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$57.98 +0.25 (+0.42%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services. The Specialties segment provides bromine-based specialty chemicals, including elemental bromine, alkyl and inorganic bromides, brominated powdered activated carbon, and other bromine fine chemicals; lithium specialties, such as butyllithium and lithium aluminum hydride; develops and manufactures cesium products for the chemical and pharmaceutical industries; and zirconium, barium, and titanium products for pyrotechnical applications that include airbag initiators. The Ketjen segment offers clean fuels technologies (CFT), which is composed of hydroprocessing catalysts (HPC) together with isomerization and akylation catalysts; fluidized catalytic cracking (FCC) catalysts and additives; and performance catalyst solutions (PCS), which is composed of organometallics and curatives. The company serves the energy storage, petroleum refining, consumer electronics, construction, automotive, lubricants, pharmaceuticals, and crop protection markets. Albemarle Corporation was founded in 1887 and is headquartered in Charlotte, North Carolina.ARC Document Solutions NYSE:ARCARC Document Solutions, Inc., a digital printing company, provides digital printing and document-related services in the United States. It provides managed print services, that places, manages, and optimizes print and imaging equipment in customers' offices, job sites, and other facilities; and cloud-based document management software and other digital hosting services. The company also provides professional services and software services to re-produce and distribute large-format and small-format documents, and specialized graphic color printing. In addition, it engages in the sale and supply of equipment; and provides ancillary services. The company operates service centers in the United States, Canada, China, the United Kingdom, India, and the United Arab Emirates. It serves local restaurant owners, construction subcontractors, international retailers, regional energy companies, and largest school districts, as well as retail, technology, energy, education, hospitality, public utilities, and others. The company was formerly known as American Reprographics Company and changed its name to ARC Document Solutions, Inc. in 2012. ARC Document Solutions, Inc. was founded in 1988 is headquartered in San Ramon, California.Cardiol Therapeutics NASDAQ:CRDL$1.08 +0.01 (+0.93%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.08 0.00 (-0.37%) As of 04/25/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
